...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>European review for medical and pharmacological sciences. >The effect of DC+CIK combined therapy on rat liver cancer model and its modulatory effect on immune functions
【24h】

The effect of DC+CIK combined therapy on rat liver cancer model and its modulatory effect on immune functions

机译：DC + CIK联合治疗对大鼠肝癌模型的影响及其对免疫功能的调节作用

获取原文
   

获取外文期刊封面封底 >>

       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

OBJECTIVE: Primary liver cancer is a sort of the most common solid tumors occurred in the digestive system. The incidence and mortality rate maintain at a high level, thus leading to heavy economic and psychological burdens for patients. Next-generation biological therapy, such as cellular immune treatment, improves the medicine efficacy. Cytokine-induced killer (CIK) cells can effectively clear residual tumor lesion and inhibit metastasis or recurrence. Dendritic cells (DCs) can specifically eliminate tumor cells via modulating cellular immune function of the host. This study aimed to investigate the function of DC+CIK combined treatment on rat liver model and its effect on immune functions. MATERIALS AND METHODS: RH-35 tumor cell was used to prepare live cancer model on Wistar rats, which were further divided into control, CIK and DC+CIK groups, in which rats received autograft CIK and DCs. Tumor size was later measured along with liver function index. The secretions of IFN-γ, IL-4, and TNF-α were measured by Real-time PCR and Western blotting. RESULTS: Both CIK and DC+CIK treatment significantly reduced tumor size and improved liver function, increased secretion of IFN-γ, IL-4, and TNF-α, decreased Bcl-2 expression and enhanced Bax expression (p < 0.05 compared to control group). DC+CIK combined therapy presented significantly better efficacy than CIK did. CONCLUSIONS: DC+CIK combined therapy can protect the host against tumors invasion via modulating body immune or liver function, regulating apoptosis/anti-apoptosis balance, which shows better efficacy than CIK alone, and can work as a novel biological therapeutic strategy for liver cancer.
机译：目的：原发性肝癌是消化系统中最常见的实体瘤。发病率和死亡率维持在较高水平，从而给患者带来沉重的经济和心理负担。下一代生物疗法，例如细胞免疫疗法，提高了药效。细胞因子诱导的杀伤细胞（CIK）可以有效清除残留的肿瘤病变并抑制转移或复发。树突状细胞（DC）可以通过调节宿主的细胞免疫功能特异性清除肿瘤细胞。本研究旨在探讨DC + CIK联合治疗对大鼠肝模型的功能及其对免疫功能的影响。材料与方法：使用RH-35肿瘤细胞在Wistar大鼠上建立活癌模型，将其进一步分为对照组，CIK组和DC + CIK组，其中大鼠接受自体移植的CIK和DC。随后测量肿瘤大小以及肝功能指数。通过实时PCR和蛋白质印迹法测量IFN-γ，IL-4和TNF-α的分泌。结果：CIK和DC + CIK治疗均显着降低了肿瘤大小，改善了肝功能，增加了IFN-γ，IL-4和TNF-α的分泌，降低了Bcl-2表达并增强了Bax表达（与对照组相比，p <0.05）组）。 DC + CIK联合疗法的疗效明显优于CIK。结论：DC + CIK联合疗法可通过调节机体免疫或肝功能，调节细胞凋亡/抗凋亡平衡来保护宿主免受肿瘤侵袭，其疗效优于单独使用CIK，并可作为一种新的肝癌生物学治疗策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号